HOME >> MEDICINE >> NEWS
Are some medicines so good they should be free? In diabetes, the answer may be yes

ho has never had a stroke.

"In our society, we often pay for health strategies that provide health benefits at a reasonable but added cost," says Rosen. "But this strategy goes even further: it saves lives and saves money. Removing patient financial barriers for ACE inhibitors prevents expensive and life-threatening complications, and improves quality of life. In so doing, patients pay less, Medicare pays less, and everyone wins. It's a virtual no-brainer."

Even if the availability of free ACE inhibitors didn't cause a major upswing in the use of the drugs by these patients, the strategy would still pay for itself, Rosen says.

"If only 7 percent more people started taking ACE inhibitors when they were offered at no cost, Medicare would still save money. The more people that take advantage of the no-cost drugs, the bigger the savings for Medicare over the long term. And of course, each patient has a lower risk of heart attack, stroke, or kidney failure."

The researchers ran the computer model many times, making changes each time in 38 different variables. Ninety percent of the time, they found that no-cost ACE inhibitors saved money; the other 10 percent of the time they were cost-effective -- costing less than $20,000 per QALY gained.

The authors also looked at costs and savings on a societal, rather than Medicare, level -- including patients' productivity and the cost of caregiving for people with health-related disability. The savings were even greater than Medicare savings alone.

If Medicare were able to purchase ACE inhibitors for all its diabetes patients at the same low cost that the Department of Defense pays, the government's lifetime savings on each patient would be even higher. And it would only take a 1.1 percent increase in patient use of ACE inhibitors to make the program cost-saving.

Rosen notes that the analysis doesn't even take into account more recent evidence that ACE inhibitors can also
'"/>

Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System
18-Jul-2005


Page: 1 2 3 4 5

Related medicine news :

1. New drug development facility helps move medicines to market
2. To get blood pressure under control, combination of medicines may be best
3. Italian doctors get their information on medicines from drug company sales reps
4. Most children in US hospitals receive medicines off-label
5. Study finds differences between blood pressure medicines and newly-diagnosed diabetes
6. Liverpool launches 20 million project to develop medicines for children
7. National study compares delivery methods of schizophrenia medicines
8. More than half of older diabetics lack medicines that protect kidneys and heart
9. Conference calls for global approach to risk management in medicines, food, environment
10. UQ research will move medicines to market more quickly
11. Racial disparities in access to medicines increase after implementation of prescription surveillance

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Are some medicines good they should free diabetes the answer may yes

(Date:8/31/2015)... ... August 31, 2015 , ... ... at Monmouth, was one of the first doctors in the area to perform ... new approach have been impressive: faster recovery, decreased immediate and long-term pain, and ...
(Date:8/31/2015)... ... ... Docs Presents, Dr. Michael Betsy! Dr. Betsy has been reviewed and approved as an ... from Don Bosco Prep in 1990 and was Class Salutatorian. He earned Varsity letters ... senior year. He was inducted into the National Honor Society as a sophomore, was ...
(Date:8/31/2015)... ... 31, 2015 , ... With the FCPX LUT Soft pack from Pixel Film Studios, editors can ... that contains a mathematical formula for modifying an image. The LUT changes every pixel's color ... LUT files. , FCPX LUT Soft requires Final Cut Pro X 10.2 or newer. ...
(Date:8/31/2015)... ... August 31, 2015 , ... How can healthcare meet the ... costs? , In a commentary for The American Journal of Managed Care ... “clinical efficacy,” which would bind parties together in agreements to intervene at the ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... and digital marketing communications company announced today that it has officially launched a ... President, the new website and brand refresh are more closely aligned with the ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3
(Date:8/31/2015)... Aug. 31, 2015  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced that ... Chicago -based Rush University Medical Center ... of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) ... complete cervical spinal cord injury (SCI). This represents ...
(Date:8/31/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused ... the treatment of diseases of the central nervous system ... submission has passed review by the US Food and ... 1 clinical trial in patients with metastatic colon cancer ... 31 December 2015. Bionomics, CEO & Managing ...
(Date:8/30/2015)... ANDOVER, Massachusetts y LONDRES, August 30, 2015 ... conectada ofrece una visión holística de l ... de todo el trayecto   ... anunciado hoy el debut europeo de IntelliSpace Cardiovascular ... información que ofrece sofisticadas herramientas para acceder, analizar y ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3
Cached News: